Retatrutide: Results, Myths, and Why Not to Buy It Online

Retatrutide is an experimental weight-loss drug from Eli Lilly, and no country has approved it. In Lilly’s largest trial, people on the top dose lost about 28% of their body weight over 80 weeks. Lilly plans to ask the FDA for approval in early 2027, so any retatrutide sold today online, at a med spa or as “research use only” was made outside the trials, and no one has checked its dose, its purity, or whether it’s retatrutide at all.

What it is

Retatrutide is one drug that mimics three gut hormones: GLP-1, GIP and glucagon. That’s why it’s sometimes called a “triple agonist.” There’s no such thing as “GLP-3”; that name is a myth. Acting on three hormones is why the weight loss is larger, and it’s also why the side effects aren’t milder.

What the trials show

In Lilly’s TRIUMPH-1 trial, people who stayed on the top 12 mg dose lost about 28% of their body weight over 80 weeks. Counting everyone who started, including people who stopped, the average was 25%, against about 4% on placebo. For comparison on the same measure, tirzepatide (Zepbound) averaged about 21% in its main trial.

Four common myths

• “It burns fat but spares muscle.” The published data don’t show that. The share of lean mass lost is in the same range as other drugs in this class. No GLP-1 gets a pass on muscle.
• “It has fewer stomach side effects than Wegovy or Zepbound.” No: they’re similar, possibly worse. At the top dose, about 28% had nausea and about 34% diarrhea. A newer side effect also showed up in the large trials: dysesthesia, strange or painful skin sensations, in about one in five people on 12 mg.
• “It makes Zepbound and Wegovy obsolete.” No. People respond to and tolerate these drugs very differently, and some do better on tirzepatide.
• “It’s basically proven.” Wegovy and Zepbound have years of real-world use in millions of people. Retatrutide has trial data in thousands, and new side effects are still surfacing.

Buying it online

Lilly says it has reported more than 14,000 websites, ads and listings selling retatrutide. With no approved drug to copy, whatever is in those vials has no one standing behind it. Lilly is also in court arguing that retatrutide counts as a biologic, a type of drug pharmacies can’t legally compound; as of October 2026 that case hadn’t been decided.

How to get it legally now

There are two legal routes: a clinical trial, or a program Lilly opened in August 2026 through which a doctor can request it for a small number of patients who can’t join a trial. While you wait, the approved medicines are already strong.

Sources

• Eli Lilly press release, May 21, 2026: TRIUMPH-1 results (12 mg, 80 weeks)
• Eli Lilly statements, August 2026: no regulator has approved retatrutide; more than 14,000 listings reported; the pre-approval request program
• US Court of Appeals for the Seventh Circuit, No. 26-1301: whether retatrutide is a biological product
• Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1): tirzepatide